Despite Bionano Genomics' robust revenue growth and future p...

Despite Bionano Genomics' robust revenue growth and future projections, its P/S ratio is surprisingly low, indicating investor skepticism about the company's ability to meet these expectations. The market seems to be factoring in certain risks, leading to investor hesitation.